Edwards Lifesciences (0REN) Share Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0REN Analyst Ratings

Moderate Buy

8 Buy

10 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Edwards

Lifesciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0REN Stock 12 Month Forecast

Average Price Target

CHF65.72

Based on 18 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is CHF65.72 with a high forecast of CHF74.53 and a low forecast of CHF58.80. The average price target represents a ― change from the last price of ―.

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

Highest Price TargetCHF74.53

Average Price TargetCHF65.72

Lowest Price TargetCHF58.80

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Reiterated

04/16/25

Reiterated

04/15/25

Reiterated

04/15/25

Reiterated

04/14/25

Reiterated

04/11/25

Reiterated

03/28/25

Reiterated

03/20/25

Reiterated

03/20/25

Reiterated

03/19/25

Reiterated

02/12/25

xxxxxxxxxxxxx

Robbie Marcus

J.P. Morgan

CHF63.8→CHF65.44

Hold

―

Reiterated

02/12/25

Edwards Lifesciences (EW) PT Raised to $80 at JPMorganJPMorgan analyst Robbie Marcus raised the price target on Edwards Lifesciences (NYSE: EW) to $80.00 (from $78.00) while maintaining a Neutral rating.

Anthony Petrone

Mizuho Securities

CHF69.53

Buy

―

Reiterated

02/12/25

Edwards Lifesciences: Promising Growth with Strong Performance in TMTT and TAVR Segments Justifies Buy Rating

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

02/12/25

Bank of America Securities Remains a Buy on Edwards Lifesciences (EW)

William Plovanic

Canaccord Genuity

CHF55.62→CHF58.08

Hold

―

Reiterated

02/12/25

Edwards Lifesciences price target raised to $71 from $66 at CanaccordEdwards Lifesciences price target raised to $71 from $66 at Canaccord

Vijay Kumar

Evercore ISI

CHF61.35→CHF59.71

Hold

―

Reiterated

02/12/25

Evercore ISI Reaffirms Their Hold Rating on Edwards Lifesciences (EW)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Reiterated

04/16/25

Reiterated

04/15/25

Reiterated

04/15/25

Reiterated

04/14/25

Reiterated

04/11/25

Reiterated

03/28/25

Reiterated

03/20/25

Reiterated

03/20/25

Reiterated

03/19/25

Reiterated

02/12/25

xxxxxxxxxxxxx

Robbie Marcus

J.P. Morgan

CHF63.8→CHF65.44

Hold

―

Reiterated

02/12/25

Anthony Petrone

Mizuho Securities

CHF69.53

Buy

―

Reiterated

02/12/25

Edwards Lifesciences: Promising Growth with Strong Performance in TMTT and TAVR Segments Justifies Buy Rating

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

02/12/25

Bank of America Securities Remains a Buy on Edwards Lifesciences (EW)

William Plovanic

Canaccord Genuity

CHF55.62→CHF58.08

Hold

―

Reiterated

02/12/25

Edwards Lifesciences price target raised to $71 from $66 at CanaccordEdwards Lifesciences price target raised to $71 from $66 at Canaccord

Vijay Kumar

Evercore ISI

CHF61.35→CHF59.71

Hold

―

Reiterated

02/12/25

Evercore ISI Reaffirms Their Hold Rating on Edwards Lifesciences (EW)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

Which Analyst Should I Follow If I Want to Buy GB:0REN and Sell After:

1 Month

xxx

Success Rate

12/17 ratings generated profit

Average Return

+3.04%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.59% of your transactions generating a profit, with an average return of +3.04% per trade.

3 Months

xxx

Success Rate

15/22 ratings generated profit

Average Return

+1.77%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +1.77% per trade.

1 Year

Suraj KaliaOppenheimer

Success Rate

21/31 ratings generated profit

Average Return

+10.63%

reiterated a buy rating 5 months ago

Copying Suraj Kalia's trades and holding each position for 1 Year would result in 67.74% of your transactions generating a profit, with an average return of +10.63% per trade.

2 Years

xxx

Success Rate

13/22 ratings generated profit

Average Return

+17.77%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 59.09% of your transactions generating a profit, with an average return of +17.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0REN Analyst Recommendation Trends

Rating

Dec 24

Jan 25

Feb 25

Mar 25

Apr 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0REN has received 10 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. 0REN average Analyst price target in the past 3 months is 65.72.

Each month's total comprises the sum of three months' worth of ratings.

0REN Financial Forecast

0REN Earnings Forecast

Next quarter’s earnings estimate for 0REN is CHF0.51 with a range of CHF0.49 to CHF0.54. The previous quarter’s EPS was CHF0.52. 0REN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.74% of the time in the same period. In the last calendar year 0REN has Outperformed its overall industry.

0REN Sales Forecast

Next quarter’s sales forecast for 0REN is CHF1.21B with a range of CHF1.17B to CHF1.23B. The previous quarter’s sales results were CHF1.16B. 0REN beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 51.97% of the time in the same period. In the last calendar year 0REN has Outperformed its overall industry.

0REN Stock Forecast FAQ

What is GB:0REN’s average 12-month price target, according to analysts?

Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 65.72.

What is GB:0REN’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:0REN, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Edwards Lifesciences a Buy, Sell or Hold?

Edwards Lifesciences has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 10 hold ratings and 0 sell ratings.

What is Edwards Lifesciences’s share price target?

The average share price target for Edwards Lifesciences is 65.72. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF74.53 ,and the lowest forecast is CHF58.80. The average share price target represents N/A Increase from the current price of N/A.

What do analysts say about Edwards Lifesciences?

Edwards Lifesciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Edwards Lifesciences?

To buy shares of GB:0REN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Edwards Lifesciences (0REN) Share Forecast & Price Target

0REN Analyst Ratings

0REN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Edwards Lifesciences

0REN Analyst Recommendation Trends

0REN Financial Forecast

0REN Earnings Forecast

0REN Sales Forecast

0REN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts